| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
JERSEY CITY, N.J.—Mitsubishi Tanabe Pharma Corporation, Inc. reported today that Mitsubishi Tanabe Pharma Development America, Inc. has initiated a Phase 3 clinical trial in the U.S. for MT-7117 (dersimelagon). The investigational oral therapy is being studied as a possible treatment option to increase pain-free light exposure in adult and adolescent patients with a history of phototoxicity — including severe pain on exposure to sunlight — from erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).
 
MT-7117 is a synthetic, non-peptide small molecule which acts as a selective agonist of melanocortin-1 receptor (MC1R). Mitsubishi Tanabe Pharma is developing MT-7117 as a potential treatment option for EPP or XLP. The company was also recently granted Orphan Drug Designation for MT-7117 by the U.S. Food and Drug Administration on June 8.
 
“Mitsubishi Tanabe Pharma group companies are working hard to advance research and development activities to deliver new therapy options that address the needs of patients fighting serious diseases,” said Atsushi Fujimoto, president of Mitsubishi Tanabe Pharma America. “Through further clinical development and potential regulatory approval, this investigative oral treatment could provide another option for patients with EPP or XLP.”
 
EPP is an inherited disorder of the heme biosynthetic pathway that results from mutations of the ferrochelatase (FECH) gene. Less common is XLP, which results from mutations in the aminolevulinic acid synthase-2 gene. Both diseases are characterized by accumulation of protoporphyrin in blood, erythrocytes and tissues, and by cutaneous photosensitivity.
 
EPP and XLP usually present in early childhood, with extremely painful phototoxic reactions which are preceded by a prodrome of tingling, stinging and/or burning of sun-exposed skin. The onset of prodromal symptoms after direct sun exposure varies but may occur in less than 10 minutes. And continued exposure to sunlight following the onset of prodromal symptoms will lead to phototoxicity-induced pain.
 
The global Phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, safety and tolerability of MT-7117 in approximately 159 people with EPP or XLP over a 26-week treatment period. The primary objective of the study is to investigate efficacy of MT-7117 on time to first onset of prodromal symptoms associated with sunlight exposure in adults and adolescents with EPP or XLP.
 
The Phase 3 study design will leverage experience and knowledge obtained from an earlier Phase 2 study, which assessed the efficacy, safety and tolerability of MT-7117 in 102 people with EPP. The study consisted of a two-week screening period, a 16-week double-blind treatment period and a six-week follow-up period at Week 22.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue